Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.
about
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cellsTumor-derived exosomes in cancer progression and treatment failureThe impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasisOxidative stress, epigenetics, and cancer stem cells in arsenic carcinogenesis and preventionEpimorphin-induced MET sensitizes ovarian cancer cells to platinumWithaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cellsFunctional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenExtracts from Curcuma zedoaria Inhibit Proliferation of Human Breast Cancer Cell MDA-MB-231 In Vitro.Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cellsMetformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.Ginsenoside 20(S)-Rg3 targets HIF-1α to block hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells.Sensitization of ovarian cancer cells to cisplatin by gold nanoparticlesDown-regulation of HtrA1 activates the epithelial-mesenchymal transition and ATM DNA damage response pathwaysOverexpression of CD157 contributes to epithelial ovarian cancer progression by promoting mesenchymal differentiation.The T-box transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cellsEnhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine.Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.Notch signaling in serous ovarian cancer.Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability.TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.Downregulation of serine protease HTRA1 is associated with poor survival in breast cancerFailure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia.Metastatic breast cancer cells in the bone marrow microenvironment: novel insights into oncoprotection.Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.Interleukin-6 as a therapeutic target in human ovarian cancerInhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer.Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis.Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples.Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.Natural products as potential cancer therapy enhancers: A preclinical update.Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cellsThe lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer.An analogy between the evolution of drug resistance in bacterial communities and malignant tissues.The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers.Spontaneous spheroid budding from monolayers: a potential contribution to ovarian cancer disseminationMesenchymal stem-like cells isolated from human esophageal carcinoma and adjacent non-cancerous tissues.miR-203 Functions as a Tumor Suppressor by Inhibiting Epithelial to Mesenchymal Transition in Ovarian Cancer
P2860
Q26748850-60129E02-1B7F-448E-83AB-C808D3549E7CQ26785408-6D2692CC-A30C-4B88-A4AE-690B1CF85574Q28388257-EE0B588F-C6A3-479D-944E-66D9A07251AEQ28393227-03B8858F-5798-43BE-B286-6538367F4942Q28536991-2A8D446B-4754-4F58-8770-860DD806DFE6Q28543359-499C0EC7-9882-4045-80B0-E0EAA74B7032Q28546856-6DC8DBA0-495D-4689-BBE8-3CCFBF90B066Q30446755-05E5DBE3-CB48-41A8-9DEB-31628F9157FCQ33628532-6EA4D1ED-5A19-4AF7-938D-E4D5BC2B9274Q33634352-833EACE9-1626-45F5-8604-D8D1A9E4B0D3Q33865464-30C8A420-EA99-4F86-B41D-CB6FD27B672DQ33890763-3CCAF08C-A2FD-43A3-B5EE-B7E33DDB51D5Q34149627-AC247424-C29D-4FBC-B296-DFB3B3990086Q34227763-22F31788-04FA-4998-AB4A-A64ED7FCC7EBQ34326145-72BA9951-0B55-4058-8EFF-CEFAE0BB634DQ34391763-542F62FC-F152-456B-8ACD-E9BB7749EFBFQ34397165-81B99FEA-084B-4B33-9233-B468AA90008FQ34402129-B253B881-3D6B-4451-9B46-69B1491AEA65Q34442318-641A7453-1AA3-4901-8366-E75A5F1F7E57Q34491211-0E163723-D1AD-44F0-86AB-C726E9421D25Q34516879-1DB7A007-BB58-4586-A5DC-05A220A3DB9BQ34545399-BFAAB653-5B95-4459-8E34-CB57E7466C35Q34624405-76E7162A-672E-4F6A-8E7C-4EEA3CA2950AQ34666305-C9C4914A-0343-4696-B375-5D194159B9E1Q34786452-F60BCD75-9C3B-43F6-BC38-C446F449629CQ35112032-998907DF-997A-4A50-9FC3-65C94E930E20Q35145140-E0F37CCC-0691-4D9B-8084-10C733225B74Q35239088-8A8B9B00-15B8-4875-87F6-BAB1C353A404Q35605854-0891A0A5-4AB5-465F-8EBE-24211450C72BQ35703549-9EC0D539-7A56-43EA-9320-A1293883289FQ35772988-7483A10D-17E8-4634-9E4A-EDC7E535404FQ35889626-8BE79E20-9E47-430B-9878-C640E45F219CQ36165835-86E78CE6-A51D-48AF-93E7-81F936533935Q36265840-6A1DA24A-31DF-4C3C-BEFD-35A71FA85278Q36356007-79EE1F83-EF89-4E59-AE93-32BED3C72D34Q36369411-5E2F1FE3-7D0A-45D2-8560-1C3438CC0066Q36372971-2EE216BC-538E-4AFD-A5DC-71B56C703F32Q36425908-0A0D62CC-06D8-48BE-AA14-188DDC8E72E0Q36475443-458C0613-527B-41C4-8FCB-6033D1571DF9Q36497625-2B8003CE-C8B9-445B-9ED9-81856CCC35F3
P2860
Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epithelial mesenchymal transit ...... e in recurrent ovarian cancer.
@en
Epithelial mesenchymal transit ...... e in recurrent ovarian cancer.
@nl
type
label
Epithelial mesenchymal transit ...... e in recurrent ovarian cancer.
@en
Epithelial mesenchymal transit ...... e in recurrent ovarian cancer.
@nl
prefLabel
Epithelial mesenchymal transit ...... e in recurrent ovarian cancer.
@en
Epithelial mesenchymal transit ...... e in recurrent ovarian cancer.
@nl
P2093
P1476
Epithelial mesenchymal transit ...... e in recurrent ovarian cancer.
@en
P2093
Jock Findlay
Khalid Abubaker
Michael Quinn
Nuzhat Ahmed
P304
P356
10.2174/156800910791190175
P577
2010-05-01T00:00:00Z